



**Innovative back microsurgery**

**Press release**

## Vexim Announces 2015 First Half Sales Results

Sales of €6.1m, growing +24% year-over-year  
Further Growth Anticipated in Second Half of 2015

**Toulouse, July 28, 2015 - VEXIM (FR0011072602 – ALVXM / PEA-PME eligible)**, a medical device company specializing in the minimally invasive treatment of vertebral fractures, announces today its consolidated sales results for the first six months of 2015.


### Continued growth in S1 2015

(€ '000s)	Quarter Ended June 30, 2015			Half-year Ended June 30, 2015		
	Q2 2015	Q2 2014	Change (%)	H1 2015	H1 2014	Change (%)
Sales	<b>3,376</b>	2,779	<b>+21%</b>	<b>6,096</b>	4,907	<b>+24%</b>

In the first half of 2015, VEXIM's sales reached € 6.1 million, up 24% from the same period in 2014. This increase in sales was primarily driven by the continued penetration of our SpineJack® technology across all geographies currently covered by VEXIM. Over 4,400 SpineJack® implants were sold in the first six months of 2015, up 19% from the 3,733 sold in the 2014 first half. This brings the total number of implants sold since SpineJack® was launched in late 2010 to more than 21,400.

The first half 2015 results also include more than 100 Masterflow™ surgeries performed in Europe and the US during this period.

Vincent Gardès, CEO of VEXIM, commented: *"We delivered a strong first half performance with more than 20% growth, and have now achieved at least 20% growth for the last 14 quarters. We continue to gain momentum with a record sales month of €1.3 million for the month of June. While we are pleased with our recent performance, we anticipate further market penetration and growth in Europe and Internationally in the second half of the year."*



## Next Communication:

First Half 2015 Financial results: September 30th 2015\*

\*indicative dates

### About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholder, Truffle Capital<sup>1</sup> and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland, the United Kingdom and United States, as well as distributors in Turkey, Argentina, Taiwan, Belgium, Estonia, Poland, Portugal, South Africa, Saudi Arabia, Colombia, Panama, Venezuela, Chile, Peru and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil. Vexim has been listed on NYSE Alternext Paris since May 2012.

For further information, please visit [www.vexim.com](http://www.vexim.com)

### SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

### Contacts

#### VEXIM

**Vincent Gardès**

CEO

[investisseur@vexim.com](mailto:investisseur@vexim.com)

Tel: +33 5 61 48 48 38

#### Alize RP

Relations presse

**Caroline Carmagnol / Wendy Rigal**

[vexim@alizerp.com](mailto:vexim@alizerp.com)

Tél : +33 1 44 54 36 66

+33 6 48 82 18 94

#### LifeSci Advisors LLC

Investor Relations

**Michael Wood**

[www.lifesciadvisors.com](http://www.lifesciadvisors.com)

+1 646 597 6983



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM



<sup>1</sup> Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit [www.truffle.fr](http://www.truffle.fr) and [www.fcpi.fr](http://www.fcpi.fr).